The Hybridoma Core Facility was established to provide investigators at the Lerner Research Institute with a resource for monoclonal antibody production. The facility also provides consultation services to assist the investigator in all aspects of monoclonal antibody production. The services are performed under strict QC guidelines appropriate for antibodies that may have commercial potential.
There are two phases of monoclonal antibody production: the development of the hybridoma cell line and production of the monoclonal antibody from the established hybridoma cell line. Currently, the HCF offers three methods for monoclonal antibody production from hybridoma cell lines, two in vitro methods (tissue culture and the Integra system) and one in vivo method (ascites production). In the last few years there has been a move in the scientific community to seek alternative methods to avoid or minimize the use of animals in research. The HCF will only use the in vivo ascites method if the in vitro methods fail. The majority of hybridoma cell lines will grow in vitro; the choice of method depends on the amount, concentration, and purity of antibody required. Hybridoma cell lines that do not grow or produce antibody by in vitro methods, will require the in vivo ascites method. The HCF will require the investigator to obtain an Animal Research Committee (ARC) approved protocol for use of ascites production in the context of their research.
Polyclonal antibody production is offered on a limited basis, dependent on available space in the BRU.
For information on antigen preparation for monoclonal and polyclonal antibody production please call Earl Poptic. Feedback and suggestions: email poptice@ccf.org
